VALN - Dynavax adjuvant used in newly approved COVID-19 shot in India

Biological E. Limited has won the Indian regulatory approval for CORBEVAX, a protein subunit COVID-19 vaccine designed to use the CpG 1018 adjuvant of the Dynavax Technologies (NASDAQ:DVAX). Dynavax (DVAX) shares have added ~1.5% in the pre-market. Developed by Biological E. in partnership with Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas, CORBEVAX is based on the receptor-binding domain of the spike protein of the coronavirus. The Hyderabad-based company plans to manufacture 75M doses of CORBEVAX per month and anticipates over 100M doses per month from February 2022. In July, Dynavax (DVAX) and Biological E. announced a partnership to supply CpG 1018 for use in CORBEVAX. The commercial supply agreement extends through 2022. In addition, French biotech, Valneva (NASDAQ:VALN) also uses Dynavax's CpG 1018 adjuvant in its COVID-19 vaccine candidate, which has already generated positive initial data in a Phase 3 trial.

For further details see:

Dynavax adjuvant used in newly approved COVID-19 shot in India